Merck (NYSE: MRK) reported Q2 EPS of ($0.13), $0.14 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $16.6 billion versus the consensus estimate of $16.41 billion.

GUIDANCE:

Merck sees FY2026 EPS of $2.66-$2.76, versus the consensus of $2.76.

For earnings history and earnings-related data on Merck (MRK) click here.